NCT07530887 2026-04-15
NORMA-2
The Netherlands Cancer Institute
Phase 3 Recruiting
Clinical Trials
15 trialsNCT02821013 2026-04-14
STOP-GAP
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT05727904 2026-04-03
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics, Inc.
Phase 3 Recruiting
NCT06500455 2026-04-03
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Phase 3 Recruiting
NCT05549297 2026-02-25
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Immunocore Ltd
Phase 3 Recruiting
NCT06246916 2026-02-19
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07015190 2026-02-18
Neoadjuvant Darovasertib in Primary Uveal Melanoma
IDEAYA Biosciences
Phase 3 Recruiting
NCT07221734 2026-01-21
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
mAbxience Research S.L.
Phase 3 Recruiting
NCT03567889 2025-12-17
NeoDREAM
Philogen S.p.A.
Phase 3 Recruiting
NCT06794775 2025-12-12
SWE-NEO
Karolinska University Hospital
Phase 3 Recruiting
NCT05522660 2025-12-11
USZ-STRIKE
ETOP IBCSG Partners Foundation
Phase 3 Recruiting
NCT05868707 2025-07-25
OH2 Injection in Melanoma
Binhui Biopharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT05899465 2025-03-18
PRIME
University of Aarhus
Phase 3 Recruiting
NCT06008106 2024-06-28
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting